An oncology-focused biopharmaceutical company that develops and sells medicines for blood cancers, including Brukinsa, used to treat leukemia and lymphoma. Founded in Beijing in 2010 by John Oyler and Xiaodong Wang, it was originally called BeiGene — a blend of "Beijing" and "gene" — before rebranding as BeOne in 2024, a name chosen to reflect its mission against cancer: "Be" stands for patients' goal to be free of disease, and "One" for uniting people in that fight.
Select a row to see that insider’s individual transactions. † Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -222.0K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.